330 related articles for article (PubMed ID: 16682724)
1. Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer.
Linden HM; Stekhova SA; Link JM; Gralow JR; Livingston RB; Ellis GK; Petra PH; Peterson LM; Schubert EK; Dunnwald LK; Krohn KA; Mankoff DA
J Clin Oncol; 2006 Jun; 24(18):2793-9. PubMed ID: 16682724
[TBL] [Abstract][Full Text] [Related]
2. Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer.
Linden HM; Kurland BF; Peterson LM; Schubert EK; Gralow JR; Specht JM; Ellis GK; Lawton TJ; Livingston RB; Petra PH; Link JM; Krohn KA; Mankoff DA
Clin Cancer Res; 2011 Jul; 17(14):4799-805. PubMed ID: 21750198
[TBL] [Abstract][Full Text] [Related]
3. Feasibility and predictability of perioperative PET and estrogen receptor ligand in patients with invasive breast cancer.
Gemignani ML; Patil S; Seshan VE; Sampson M; Humm JL; Lewis JS; Brogi E; Larson SM; Morrow M; Pandit-Taskar N
J Nucl Med; 2013 Oct; 54(10):1697-702. PubMed ID: 23970364
[TBL] [Abstract][Full Text] [Related]
4. PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer.
Dehdashti F; Mortimer JE; Trinkaus K; Naughton MJ; Ellis M; Katzenellenbogen JA; Welch MJ; Siegel BA
Breast Cancer Res Treat; 2009 Feb; 113(3):509-17. PubMed ID: 18327670
[TBL] [Abstract][Full Text] [Related]
5. Estrogen Receptor Binding (18F-FES PET) and Glycolytic Activity (18F-FDG PET) Predict Progression-Free Survival on Endocrine Therapy in Patients with ER+ Breast Cancer.
Kurland BF; Peterson LM; Lee JH; Schubert EK; Currin ER; Link JM; Krohn KA; Mankoff DA; Linden HM
Clin Cancer Res; 2017 Jan; 23(2):407-415. PubMed ID: 27342400
[TBL] [Abstract][Full Text] [Related]
6. Positron emission tomographic assessment of "metabolic flare" to predict response of metastatic breast cancer to antiestrogen therapy.
Dehdashti F; Flanagan FL; Mortimer JE; Katzenellenbogen JA; Welch MJ; Siegel BA
Eur J Nucl Med; 1999 Jan; 26(1):51-6. PubMed ID: 9933662
[TBL] [Abstract][Full Text] [Related]
7. A phase 1b study evaluating the effect of elacestrant treatment on estrogen receptor availability and estradiol binding to the estrogen receptor in metastatic breast cancer lesions using
Jager A; de Vries EGE; der Houven van Oordt CWM; Neven P; Venema CM; Glaudemans AWJM; Wang Y; Bagley RG; Conlan MG; Aftimos P
Breast Cancer Res; 2020 Sep; 22(1):97. PubMed ID: 32912274
[TBL] [Abstract][Full Text] [Related]
8. Can fluorine-18 fluoroestradiol positron emission tomography-computed tomography demonstrate the heterogeneity of breast cancer in vivo?
Yang Z; Sun Y; Zhang Y; Xue J; Wang M; Shi W; Zhu B; Hu S; Yao Z; Pan H; Zhang Y
Clin Breast Cancer; 2013 Oct; 13(5):359-63. PubMed ID: 23787040
[TBL] [Abstract][Full Text] [Related]
9. Between-patient and within-patient (site-to-site) variability in estrogen receptor binding, measured in vivo by 18F-fluoroestradiol PET.
Kurland BF; Peterson LM; Lee JH; Linden HM; Schubert EK; Dunnwald LK; Link JM; Krohn KA; Mankoff DA
J Nucl Med; 2011 Oct; 52(10):1541-9. PubMed ID: 21903739
[TBL] [Abstract][Full Text] [Related]
10. Metabolic flare: indicator of hormone responsiveness in advanced breast cancer.
Mortimer JE; Dehdashti F; Siegel BA; Trinkaus K; Katzenellenbogen JA; Welch MJ
J Clin Oncol; 2001 Jun; 19(11):2797-803. PubMed ID: 11387350
[TBL] [Abstract][Full Text] [Related]
11. Positron emission tomography with 2-[18F]Fluoro-2-deoxy-D-glucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy.
Mortimer JE; Dehdashti F; Siegel BA; Katzenellenbogen JA; Fracasso P; Welch MJ
Clin Cancer Res; 1996 Jun; 2(6):933-9. PubMed ID: 9816253
[TBL] [Abstract][Full Text] [Related]
12. Utility of
Lin FI; Gonzalez EM; Kummar S; Do K; Shih J; Adler S; Kurdziel KA; Ton A; Turkbey B; Jacobs PM; Bhattacharyya S; Chen AP; Collins JM; Doroshow JH; Choyke PL; Lindenberg ML
Eur J Nucl Med Mol Imaging; 2017 Mar; 44(3):500-508. PubMed ID: 27872957
[TBL] [Abstract][Full Text] [Related]
13. Comparison of 18F-FES, 18F-FDG, and 18F-FMISO PET Imaging Probes for Early Prediction and Monitoring of Response to Endocrine Therapy in a Mouse Xenograft Model of ER-Positive Breast Cancer.
He S; Wang M; Yang Z; Zhang J; Zhang Y; Luo J; Zhang Y
PLoS One; 2016; 11(7):e0159916. PubMed ID: 27467716
[TBL] [Abstract][Full Text] [Related]
14.
Wang Y; Ayres KL; Goldman DA; Dickler MN; Bardia A; Mayer IA; Winer E; Fredrickson J; Arteaga CL; Baselga J; Manning HC; Mahmood U; Ulaner GA
Clin Cancer Res; 2017 Jun; 23(12):3053-3060. PubMed ID: 28011460
[No Abstract] [Full Text] [Related]
15. Quantitative imaging of estrogen receptor expression in breast cancer with PET and 18F-fluoroestradiol.
Peterson LM; Mankoff DA; Lawton T; Yagle K; Schubert EK; Stekhova S; Gown A; Link JM; Tewson T; Krohn KA
J Nucl Med; 2008 Mar; 49(3):367-74. PubMed ID: 18287268
[TBL] [Abstract][Full Text] [Related]
16.
Peterson LM; Kurland BF; Yan F; Jiresova AN; Gadi VK; Specht JM; Gralow JR; Schubert EK; Link JM; Krohn KA; Eary JF; Mankoff DA; Linden HM
J Nucl Med; 2021 Feb; 62(2):184-190. PubMed ID: 32591490
[TBL] [Abstract][Full Text] [Related]
17. Measuring residual estrogen receptor availability during fulvestrant therapy in patients with metastatic breast cancer.
van Kruchten M; de Vries EG; Glaudemans AW; van Lanschot MC; van Faassen M; Kema IP; Brown M; Schröder CP; de Vries EF; Hospers GA
Cancer Discov; 2015 Jan; 5(1):72-81. PubMed ID: 25380844
[TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamic imaging guides dosing of a selective estrogen receptor degrader.
Heidari P; Deng F; Esfahani SA; Leece AK; Shoup TM; Vasdev N; Mahmood U
Clin Cancer Res; 2015 Mar; 21(6):1340-7. PubMed ID: 25609068
[TBL] [Abstract][Full Text] [Related]
19. Factors influencing the uptake of 18F-fluoroestradiol in patients with estrogen receptor positive breast cancer.
Peterson LM; Kurland BF; Link JM; Schubert EK; Stekhova S; Linden HM; Mankoff DA
Nucl Med Biol; 2011 Oct; 38(7):969-78. PubMed ID: 21982568
[TBL] [Abstract][Full Text] [Related]
20. The Application of 18 F-FES PET in Clinical Cancer Care : A Systematic Review.
Huang YT; Chen TW; Chen LY; Huang YY; Lu YS
Clin Nucl Med; 2023 Sep; 48(9):785-795. PubMed ID: 37482660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]